Today's Rundown GSK pays $50M for 2 solid tumor cell therapies from Immatics Everest hires ex-Lilly leader to oversee push for Chinese market Five Prime grabs $5M lifeline in Seattle Genetics ADC deal [Sponsored] Executive Interviews at J.P. Morgan 2020 Spruce nets $88M to push rare disease drug into late-stage trial Eisai unit H3 Biomedicine poaches Kura Oncology founder as CMO How a discovery in 'junk' DNA could protect against heart disease CMR Surgical rolls out modular surgery robot to NHS hospitals UPDATED Coronavirus tracker: Biopharmas apply new tech to treatment hunt; Smith & Nephew forecast depends on virus Featured Story | | | Thursday, February 20, 2020 GlaxoSmithKline has struck a deal to access two Immatics T-cell receptor (TCR) therapeutics. The deal will see GSK pay $50 million (€46 million) upfront and commit to $550 million in milestones for TCRs against two solid tumor targets identified by Immatics. |
|
|---|
|
| | AlivaMab® Mouse: Establishing the Fastest and Most De-Risked Path from Antibody Drug Discovery to Market. AlivaMab Mouse from Ablexis is a trusted and demonstrably better platform for the successful and efficient discovery of therapeutic-quality antibodies. It is uniquely differentiated to deliver quality, speed and value for antibody drug discovery projects, even the most challenging. Contact us at [email protected] to learn more. ablexis.com |
Top Stories Thursday, February 20, 2020 Everest Medicines has named Eli Lilly veteran Kerry Blanchard as its CEO. Blanchard takes up the top job at the Shanghai-based biopharma company on the back of a career built around a 17-year spell at Lilly. Wednesday, February 19, 2020 One day after Five Prime revealed its Opdivo-paired immuno-oncology prospect failed a midstage pancreatic cancer trial, the biotech is farming out some preclinical antibodies to keep its clinical-stage pipeline alive. In exchange for $5 million upfront and many millions more promised, Seattle Genetics will develop antibody-drug conjugates based on those antibodies. Thursday, February 13, 2020 FierceBiotech sits down with some of the most informative industry leaders at JPM 2020. Thursday, February 20, 2020 In September, Spruce Biosciences reported a phase 2 win for its nonsteroid treatment in a rare endocrine disorder. Now, it’s raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults, as well as proof-of-concept trials in children. Thursday, February 20, 2020 Antonio Gualberto, M.D., Ph.D., helped found early-stage biotech Kura Oncology and ran its R&D as chief medical officer. Now, he’s moving over to fill the same role at H3 Biomedicine. Wednesday, February 19, 2020 Many human genes are referred to “junk DNA” because they aren't involved in the production of proteins. Now, researchers led by Brigham and Women’s Hospital have linked a seemingly worthless RNA molecule to atherosclerosis in a discovery they say could aid in the development of new drugs for cardiovascular disease. Wednesday, February 19, 2020 U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to National Health Service hospitals and has completed its first minimally invasive procedures in the country and the European continent. Wednesday, February 12, 2020 The effort to contain the outbreak continues even as the case count climbs. Meanwhile, biopharma is applying new technology to the hunt for a treatment, and device maker Smith & Nephew's guidance for the upcoming year depends on how the crisis plays out. Resources Sponsored by: H1 Biopharma companies don't want to go to market with a product no one knows about. H1 has homed in on the often time-consuming research and engagement phases that companies must ace for a successful launch, said Ariel Katz, co-founder of H1. Sponsored by: Clinical Ink Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Accenture Kevin Julian, senior managing director of Accenture’s life sciences practice, recently sat down with FierceBiotech to discuss market trends and Accenture’s new technology platform, INTIENT. Sponsored by: Eagle Productivity Solutions Mediocre adoption rates aren’t due to poorly designed software or lazy users. They’re the result of how skills are trained. Achieve high adoption rates for Veeva, Workday, Microstrategy or any software platform by implementing the right methodology with a focus on behavior change. Sponsored by: Blue Matter Consulting White paper describing how a biopharma company can successfully differentiate an oncology product when the clinical profile alone is not enough to get the job done. Sponsored by: Medidata To conduct a successful trial, do you need to understand the global eConsent Regulatory landscape? Sponsored by: USDM Life Sciences Details on the FDA’s upcoming Computer System Validation guidance Sponsored by: Veeva Learn how data management teams at ICON, Bioforum, and Vertex Pharmaceuticals are creating the spec and casebook in a single step, reducing study build times and effort by over 50%. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. 11th Annual SCOPE Summit: Summit for Clinical Ops Executives February 18-21, 2020 | Orlando, FL Molecular Med TRI-CON: Final Days to Register! March 1-4, 2020 | Moscone North Convention Center | San Francisco, CA BioBasics 101: The Biology of Biotech March 26-27, 2020 | Boston, MA BioBasics 101: The Biology of Biotech April 16-17, 2020 | Philadelphia, PA Drug Development Immersion April 23-24, 2020 | Boston, MA BIO International Convention June 8-11, 2020 | San Diego, CA Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now and begin Pre-Boot Camp Preparation. | Take your new medicine development skills to the next level. | 